Oral anticoagulants beyond warfarin

RH Olie, K Winckers, B Rocca… - Annual Review of …, 2024‏ - annualreviews.org
Direct oral anticoagulants (DOACs) have largely replaced vitamin K antagonists, mostly
warfarin, for the main indications for oral anticoagulation, prevention and treatment of …

COVID-19 and atrial fibrillation: Intercepting lines

M Donniacuo, A De Angelis, C Rafaniello… - Frontiers in …, 2023‏ - frontiersin.org
Almost 20% of COVID-19 patients have a history of atrial fibrillation (AF), but also a new-
onset AF represents a frequent complication in COVID-19. Clinical evidence demonstrates …

Serious bleeding in patients with atrial fibrillation using diltiazem with apixaban or rivaroxaban

WA Ray, CP Chung, CM Stein, W Smalley… - JAMA, 2024‏ - jamanetwork.com
Importance Diltiazem, a commonly prescribed ventricular rate–control medication for
patients with atrial fibrillation, inhibits apixaban and rivaroxaban elimination, possibly …

Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a …

M Grymonprez, L Carnoy, A Capiau… - European Heart …, 2023‏ - academic.oup.com
Aims The clinical relevance of common pharmacokinetic interactions with non-vitamin K
antagonist oral anticoagulants (NOACs) often remains unclear. Therefore, the impact of P …

Pharmacological aspects of antiseizure medications: From basic mechanisms to clinical considerations of drug interactions and use of therapeutic drug monitoring

C Johannessen Landmark, S Eyal, ML Burns… - Epileptic …, 2023‏ - Wiley Online Library
Antiseizure medications (ASMs) are the cornerstone of treatment for patients with epilepsy.
Several new ASMs have recently been introduced to the market, making it possible to better …

Risk for bleeding-related hospitalizations during use of amiodarone with apixaban or rivaroxaban in patients with atrial fibrillation: a retrospective cohort study

WA Ray, CP Chung, CM Stein, W Smalley… - Annals of internal …, 2023‏ - acpjournals.org
Background: Amiodarone, the most effective antiarrhythmic drug in atrial fibrillation, inhibits
apixaban and rivaroxaban elimination, thus possibly increasing anticoagulant-related risk …

Interactions between direct oral anticoagulants (DOACs) and antiseizure medications: Potential implications on DOAC treatment

R Goldstein, AR Jacobs, L Zighan, N Gronich, M Bialer… - CNS drugs, 2023‏ - Springer
The use of direct oral anticoagulants (DOACs) is increasing because of their superior
efficacy and safety compared with vitamin K antagonists. Pharmacokinetic drug interactions …

The effect of levetiracetam compared with enzyme-inducing antiseizure medications on apixaban and rivaroxaban peak plasma concentrations

R Goldstein, N Rabkin, N Buchman, AR Jacobs… - Cns Drugs, 2024‏ - Springer
Abstract Background and Objective Post-stroke epilepsy represents an important clinical
challenge as it often requires both treatment with direct oral anticoagulants (DOACs) and …

Direct-acting oral anticoagulants and antiseizure medications for atrial fibrillation and epilepsy and risk of thromboembolic events

EK Acton, S Hennessy, MA Gelfand… - JAMA …, 2024‏ - jamanetwork.com
Importance Direct-acting oral anticoagulants (DOACs) are commonly prescribed with
antiseizure medications (ASMs) due to concurrency of and the association between atrial …

Levetiracetam interaction with direct oral anticoagulants: a pharmacovigilance study

M Abou Kaoud, R Nissan, A Segev, A Sabbag, D Orion… - CNS drugs, 2023‏ - Springer
Background Levetiracetam is widely used in post-stroke epilepsy. However, it is suspected
to possess P-glycoprotein (P-gp) induction properties, and therefore, a potentially significant …